• Technology

    Technology

    Vector, target, indication getting the new combination to the clinics
  • About us

    About us

    Developing a single dose treatment for rheumatoid arthritis
  • Technology

    Technology

    Single dose treatment for chronic diseases
  • Technology

    Technology

    Vector, target, indication getting the new combination to the clinics
  • About us

    About us

    Developing a single dose treatment for rheumatoid arthritis
  • Clinical program

    Clinical program

    10 years of development getting ready for clinical trial
  • Technology

    Technology

    Single dose treatment for chronic diseases
  • HOME 767 310 02
  • HOME 767 310 01

About us

Arthrogen is an Amsterdam based biopharmaceutical company developing local gene therapy for inflammatory diseases, using viral mediated gene transfer.

Technology

The therapeutic vectors are derived from natural occurring adeno-associated viruses (AAV) that are not pathogenic in humans.

Development

It is Arthrogen’s vision that new gene therapies will contribute to the improvement of health of patients and to the reduction of healthcare cost.

Latest news

'First cohort enrolled in trial with innovative gene therapy for arthritis.' Read the full article here.

This year the Annual European Congress of Rheumatology will be held in the RAI in Amsterdam starting on June 13. Arthrogen has reserved a hospitality suite to welcome guests and interested parties throughout the congress. Would you like to have a meeting with our CEO or COO? Send an email to This email address is being protected from spambots. You need JavaScript enabled to view it..

Clinical trial ART-I02 phase Ib in NL now also open for patients with hand osteoarthritis. For more information visit proefpersoon.nl

On May 16 the 21st annual meeting of the ASGCT will start in Chicago. Arthrogen will be represented by Robert Jan Lamers (CEO), Janneke Meulenberg (COO) and Sabine van der Sanden (Senior Scientist) and they are ready to make new connections! If you would like to set up a meeting, send an email to This email address is being protected from spambots. You need JavaScript enabled to view it.

During the BioEurope Spring held at the Rai 12-14 March, Arthrogen will be represented by Robert Jan Lamers (CEO) and Janneke Meulenberg (COO).

Robert Jan Lamers (CEO) and Janneke Meulenberg (COO) will be present at the J.P. Morgan Healthcare conference, held in San Francisco in January 2018. Interesed in a 'meet&greet'? Send your request to This email address is being protected from spambots. You need JavaScript enabled to view it. for opportunities.

Arthrogen will be represented by Janneke Meulenberg (COO) and Ingrid de Vries (Research Technician) at the Cell Therapy Manufacturing & Gene Therapy Congress 6 – 7 December 2017 RAI, Amsterdam.

Robert Jan Lamers (CEO) will be present at Phacilitate Cell & Gene Therapy Europe 2017 in Berlin where Janneke Meulenberg, COO, will join the speaker panel.

Arthrogen's COO, Janneke Meulenberg, will present Wednesday September 13 a case study on: Production Platforms for RA Gene Therapy Applications at the'Cell and Gene Therapy Manufacturing' conference in London

Latest publications

Empty Capsids and Macrophage Inhibition/Depletion Increase rAAV Transgene Expression in Joints of Both Healthy and Arthritic Mice....

Intra-articular etanercept treatment in inflammatory arthritis...

Preclinical Potency and Biodistribution Studies of an AAV 5 Vector...

Safety, Biodistribution, and Efficacy of an AAV-5 Vector Encoding Human Interferon-Beta (ART-I02)...